pubmed.ncbi.nlm.nih.gov

Tumor Necrosis Factor-like Cytokine TL1A and Its Receptors DR3 and DcR3: Important New Factors in Mucosal Homeostasis and Inflammation - PubMed

Review

Tumor Necrosis Factor-like Cytokine TL1A and Its Receptors DR3 and DcR3: Important New Factors in Mucosal Homeostasis and Inflammation

Spyros I Siakavellas et al. Inflamm Bowel Dis. 2015 Oct.

Abstract

Tumor necrosis factor (TNF)-like cytokine 1A (TL1A) is a member of the TNF superfamily of proteins (TNFSF15), which signals through association with death domain receptor 3 (DR3). Decoy receptor 3 (DcR3) competes with DR3 for TL1A binding and inhibits functional signaling. These proteins are significantly upregulated in inflamed intestinal tissues, and their pathogenetic importance for inflammatory bowel disease (IBD) is suggested by accumulating evidence. TL1A/DR3 induce costimulatory signals to activated lymphocytes, including the gut-specific populations of CD4+CD161+ and CD4+CCR9+ cells, affecting all major effector pathways and inducing the mucosal upregulation of Th1, Th2, and Th17 factors. They may also participate in mucosal homeostasis and defense against pathogens through their effects on the development and function of the recently described innate lymphoid cells. T-regulatory lymphocytes highly express DR3, and they respond to TL1A stimulation also. Mechanistic studies by transgenic expression of TL1A, deletion of TL1A or DR3, and therapeutic blockade by anti-TL1A antibodies all support the critical involvement of the corresponding pathways in the pathogenesis of chronic mucosal inflammation. Wide genome association studies have identified IBD-specific polymorphisms in TNFSF15 gene, which have functional implications and serve as poor prognostic factors. Recently, TL1A blockade in mice was presented as a unique pharmacological treatment for the reversal of established intestinal fibrosis. Finally, TL1A/DR3 signaling seems to critically participate in extraintestinal inflammatory conditions that are frequently associated with IBD as part of the gut-joint-skin-eye axis. These converging lines of evidence make TL1A/DR3 a suitable model for personalized approaches to IBD therapy.

PubMed Disclaimer

Cited by

TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling.
Herro R, Miki H, Sethi GS, Mills D, Mehta AK, Nguyen XX, Feghali-Bostwick C, Miller M, Broide DH, Soloff R, Croft M. Herro R, et al. J Immunol. 2020 Nov 1;205(9):2414-2422. doi: 10.4049/jimmunol.2000665. Epub 2020 Sep 21. J Immunol. 2020. PMID: 32958689 Free PMC article.
TL1A regulates adipose-resident innate lymphoid immune responses and enables diet-induced obesity in mice.
Tougaard P, Martinsen LO, Lützhøft DO, Jensen HE, Flethøj M, Vandenabeele P, Pedersen AE, Skov S, Hansen AK, Hansen CHF. Tougaard P, et al. Int J Obes (Lond). 2020 May;44(5):1062-1074. doi: 10.1038/s41366-020-0539-1. Epub 2020 Jan 30. Int J Obes (Lond). 2020. PMID: 32001795
A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis.
Vebr M, Pomahačová R, Sýkora J, Schwarz J. Vebr M, et al. Biomedicines. 2023 Dec 6;11(12):3229. doi: 10.3390/biomedicines11123229. Biomedicines. 2023. PMID: 38137450 Free PMC article. Review.
Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It.
Migliorisi G, Vella G, Dal Buono A, Gabbiadini R, Busacca A, Loy L, Bezzio C, Vinciguerra P, Armuzzi A. Migliorisi G, et al. Cells. 2024 Jan 12;13(2):142. doi: 10.3390/cells13020142. Cells. 2024. PMID: 38247834 Free PMC article. Review.
Host-microbiota interactions in inflammatory bowel disease.
Caruso R, Lo BC, Núñez G. Caruso R, et al. Nat Rev Immunol. 2020 Jul;20(7):411-426. doi: 10.1038/s41577-019-0268-7. Epub 2020 Jan 31. Nat Rev Immunol. 2020. PMID: 32005980 Review.

Tumor Necrosis Factor-like Cytokine TL1A and Its Receptors DR3 and DcR3: Important New Factors in Mucosal Homeostasis and Inflammation - PubMed